No Data
JP Morgan Maintains Neutral on BioNTech, Lowers Price Target to $122
BioNTech Analyst Ratings
Jefferies Maintains BioNTech(BNTX.US) With Buy Rating, Maintains Target Price $150
Goldman Sachs Maintains BioNTech(BNTX.US) With Buy Rating, Maintains Target Price $137
Jefferies Reaffirms Their Buy Rating on BioNTech SE (BNTX)
Analysts Conflicted on These Healthcare Names: Aveanna Healthcare Holdings (AVAH) and BioNTech SE (BNTX)